AstraZeneca PLC (AZN)vsVerastem Inc (VSTM)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
VSTM
Verastem Inc
$7.32
-3.94%
HEALTHCARE · Cap: $742.62M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 70012% more annual revenue ($61.37B vs $87.53M). AZN leads profitability with a 17.0% profit margin vs -231.6%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
VSTM
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+83.3%
Fair Value
$34.92
Current Price
$7.32
$27.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 1775.0% year-over-year
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 13.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : VSTM
The strongest argument for VSTM centers on Revenue Growth. Revenue growth of 1775.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : VSTM
The primary concerns for VSTM are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 1.69 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while VSTM is a hypergrowth play — different risk/reward profiles.
VSTM carries more volatility with a beta of 0.32 — expect wider price swings.
VSTM is growing revenue faster at 1775.0% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 28/100), backed by strong 17.0% margins. VSTM offers better value entry with a 83.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Verastem Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Verastem, Inc., a developing-stage biopharmaceutical company focused on developing and commercializing life-enhancing drugs for cancer patients. The company is headquartered in Needham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?